• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

114870-03-0 (Fondaparinux sodium)

1

Identification

Fondaparinux sodium Fondaparinux sodium
Name Fondaparinux sodium
Formula C31H43N3Na10O49S8
MW 1728.08
CAS No. 114870-03-0
EINECS
Smiles [O-]S(N[[email protected]@H]1[[email protected]@H](OS([O-])(=O)=O)[[email protected]](O[[email protected]@H]2O[[email protected]](C([O-])=O)[[email protected]@H](O[[email protected]@H](O[[email protected]](COS([O-])(=O)=O)[[email protected]]3O)[[email protected]](NS([O-])(=O)=O)[[email protected]]3O)[[email protected]](O)[[email protected]]2O)[[email protected]@H](COS([O-])(=O)=O)O[[email protected]@H]1O[[email protected]@H]4[[email protected]](C([O-])=O)O[[email protected]@H](O[[email protected]]([[email protected]@H](COS([O-])(=O)=O)O5)[[email protected]](O)[[email protected]@H](NS([O-])(=O)=O)[[email protected]]5OC)[[email protected]](OS([O-])(=O)=O)[[email protected]]4O)(=O)=O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
Synonyms sodium (2S,3S,4R,5R,6R)-6-(((2R,3R,4R,5R,6R)-6-(((2R,3S,4S,5R,6R)-2-carboxylato-4-hydroxy-6-(((2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-((sulfonatooxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-5-(sulfonatooxy)tetrahydro-2H-pyran-3-yl)oxy)-5-(sulfonatoamino)-4-(sulfonatooxy)-2-((sulfonatooxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-3-(((2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfonatoamino)-6-((sulfonatooxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)-4,5-dihydroxytetrahydro-2H-pyran-2-carboxylate
InChI InChI=1S/C31H53N3O49S8.10Na/c1-69-27-9(33-85(48,49)50)13(37)17(6(74-27)3-71-88(57,58)59)76-31-22(83-91(66,67)68)16(40)21(24(81-31)26(43)44)79-29-10(34-86(51,52)53)19(82-90(63,64)65)18(7(75-29)4-72-89(60,61)62)77-30-15(39)14(38)20(23(80-30)25(41)42)78-28-8(32-84(45,46)47)12(36)11(35)5(73-28)2-70-87(54,55)56;;;;;;;;;;/h5-24,27-40H,2-4H2,1H3,(H,41,42)(H,43,44)(H,45,46,47)(H,48,49,50)(H,51,52,53)(H,54,55,56)(H,57,58,59)(H,60,61,62)(H,63,64,65)(H,66,67,68);;;;;;;;;;/q;10*+1/p-10/t5-,6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17-,18-,19-,20+,21+,22-,23+,24-,27+,28-,29-,30-,31-;;;;;;;;;;/m1........../s1
2

Introduction

Fondaparinux sodium is an antithrombin-dependent factor Xa inhibitor.

Background Information

Fondaparinux sodium is an antithrombin-dependent factor Xa inhibitor. ......by MedChemexpress Co., Ltd.
Fondaparinux sodium is a factor Xa inhibitor to form the high affinity binding site for the anti-coagulant factor antithrombin III (ATIII). ......by MedKoo Biosciences, Inc.
Fondaparinux is a synthetic glucopyranoside with antithrombotic activity. It selectively binds to antithrombin III, thereby potentiating the innate neutralization of activated factor X (Factor Xa) by antithrombin; a synthetic inhibitor of Factor Xa. ......by Selleck Chemicals LLC
3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance:White to off-white Solid EBNumber:EB000011867

Storage condition

Store in a tightly closed container, in a cool and dry place. by MedChemexpress Co., Ltd.

Solubility

H<sub>2</sub>O: ≥ 30 mg/mL by CHEMSCENE, LLC
H2O: ≥ 30 mg/mL by MedChemexpress Co., Ltd.
5

Mechanism and Indication

6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
Fondaparinux sodium GlaxoSmithKline Thrombosis, Venous 2008/12/11 2014/2/1 Phase 3 Clinical
Fondaparinux sodium University of Alabama at Birmingham Venous Thrombosis 2007/10/3 2012/2/1 Phase 3 Clinical
Fondaparinux sodium - Launched
7

Safety Data of Fondaparinux sodium

8

Spectral Information

9

Suppliers List

10

Related Products

Other Forms of 114870-03-0

Name CAS No Formula MW

Recommended Compounds in Factor Xa

Name CAS No Formula MW
Ozagrel (sodium) 130952-46-4 C13H11N2NaO2 250.2284
Ozagrel 82571-53-7 C13H12N2O2 228.25
Gabexate (mesylate) 56974-61-9 C17H27N3O7S 417.48
Edoxaban (tosylate monohydrate) 1229194-11-9 C31H40ClN7O8S2 738.27
Betrixaban 330942-05-7 C23H22ClN5O3 451.91
Edoxaban (tosylate) 480449-71-6 C31H38ClN7O7S2 720.26
Edoxaban 480449-70-5 C24H30ClN7O4S 548.06
5-R-Rivaroxaban 865479-71-6 C19H18ClN3O5S 435.88
Rivaroxaban 366789-02-8 C19H18ClN3O5S 435.88
Apixaban 503612-47-3 C25H25N5O4 459.5
Otamixaban 193153-04-7 C25H26N4O4 446.5
RWJ-445167 226566-43-4 C18H24N6O5S 436.49
BMS-962212 1430114-34-3 C32H28ClFN8O5 659.07
BMS-724296 872013-80-4 C26H30ClN7O 492.02
Fondaparinux (sodium) 114870-03-0 C31H44N3Na10O49S8+ 1729.08890422
FXIa-IN-1 C26H21ClN4O4 488.92
FXIa-IN-2 C26H20ClFN4O4 506.91
FXIa-IN-3 C26H19ClF2N4O4 524.9
FXIa-IN-4 C27H23ClN4O4 502.95
FXIa-IN-5 C28H21ClFN5O4 545.95

Recommended Compounds in Same Indication

Name CAS No Formula MW
Heparin 9005-49-6 C26H42N2O37S5 1134.93
VITAMIN K1 12001-79-5 C31H46O2 450.7
11

Route of Synthesis

12

References

13

More Information

Fondaparinux sodium

Tags: buy 114870-03-0 IC50 | 114870-03-0 price | 114870-03-0 cost | 114870-03-0 solubility | 114870-03-0 purchase | 114870-03-0 manufacturer | 114870-03-0 research buy | 114870-03-0 order | 114870-03-0 MSDS | 114870-03-0 chemical structure | 114870-03-0 Storage condition | 114870-03-0 molecular weight | 114870-03-0 mw | 114870-03-0 datasheet | 114870-03-0 supplier | 114870-03-0 cell line | 114870-03-0 NMR | 114870-03-0 MS | 114870-03-0 IR | 114870-03-0 solubility | 114870-03-0 Safe information | 114870-03-0 Qc and Spectral Information | 114870-03-0 Clinical Information | 114870-03-0 Clinical Trial | 114870-03-0 Route of Synthesis | 114870-03-0 storage condition | 114870-03-0 diseases and conditions | 114870-03-0 flash point | 114870-03-0 boiling point | 114870-03-0 melting point | 114870-03-0 storage condition | 114870-03-0 brand